Physician profile
James Mcdermott
NPI 1255389185
$3,261.66
in general payments reported to CMS, 2019-2025
27 companies · $546 in 2025
The $546 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $42.22 · 2021: $252 · 2022: $805 · 2023: $605 · 2024: $746 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $370.72 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $368.61 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $365.04 | 2021-2025 | |
| Astellas Pharma US INC | $327.14 | 2019-2025 | Veozah, Vesicare, Myrbetriq |
| Daiichi Sankyo INC. | $284.01 | 2019-2024 | Injectafer |
| Hologic Sales and Service, LLC | $250.91 | 2019-2025 | Fluent Fluid Management System, Aptima, Acessa Provu System |
| Amgen INC. | $213.34 | 2019-2025 | Evenity, Prolia |
| Medtronic, INC. | $145.35 | 2021-2022 | |
| Myovant Sciences INC. | $141.42 | 2021-2022 | |
| Sage Therapeutics, LLC | $114.58 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $102.50 | 2022-2025 | Solosec, Phexx, Phexxi |
| Pfizer INC. | $81.17 | 2022-2024 | |
| Amag Pharmaceuticals, INC. | $61.88 | 2019 | |
| Radius Health, INC. | $56.28 | 2022-2023 | |
| Exact Sciences Corporation | $53.62 | 2023-2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $51.07 | 2023-2024 | Nexplanon |
| Therapeuticsmd, INC. | $44.67 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.66 | 2019-2025 | |
| Millicent US INC | $35.74 | 2025 | Intrarosa, Femlyv |
| Roche Diagnostics Corporation | $30.29 | 2019 | |
| Avion Pharmaceuticals | $25.92 | 2021-2022 | |
| Menarini Silicon Biosystems, INC. | $24.21 | 2025 | Cellsearch |
| Smith+Nephew, INC. | $18.31 | 2024 | Pico 7 |
| Si-Bone, INC. | $15.79 | 2021 | |
| Agile Therapeutics, INC. | $15.19 | 2023 | Twirla |
| Duchesnay USA Incorporated | $13.40 | 2019 | |
| Minerva Surgical, INC | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcdermott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.